Clinical Trial

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Study acronym: AURORA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-23.
Trial Details
NCT Number NCT07439887
Lead Sponsor Ray Therapeutics, Inc.
Conditions Stargardt Disease
Enrollment 18 participants
Start Date 2026-01-28
Primary Completion 2030-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-15